Vertex Pharmaceuticals (VRTX Quick QuoteVRTX - Free Report) reported $2.99 billion in revenue for the quarter ended March 2026, representing a year-over-year increase of 7.8%. EPS of $4.47 for the same period compares to $4.06 a year ago.

The reported revenue represents a surprise of +0.19% over the Zacks Consensus Estimate of $2.98 billion. With the consensus EPS estimate being $4.23, the EPS surprise was +5.76%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Vertex performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues by Product- Trikafta/Kaftrio: $2.35 billion versus the five-analyst average estimate of $2.39 billion. The reported number represents a year-over-year change of -7.1%.
• Revenues- Product revenues, net: $2.99 billion versus $2.94 billion estimated by five analysts on average.
• Revenues by Product- ALYFTREK: $424.4 million versus the five-analyst average estimate of $407.85 million.

View all Key Company Metrics for Vertex here>>>

Shares of Vertex have returned -3.4% over the past month versus the Zacks S&P 500 composite's +10% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.